Sheath cryoprobe biopsy offers a potentially safer and more convenient approach for TBC and, if found to be as clinically useful as regular cryobiopsy, could indeed satisfactorily mitigate many problems associated with cryobiopsy and reduce cost substantially. It is unclear, however, whether this novel approach could in fact replace conventional cryoprobes. For example, the histologic diagnosis of diffuse parenchymal lung disease relies primarily on the assessment of microscopic features such as temporal and geographic heterogeneity in the case of usual interstitial pneumonia, which can be assessed at low magnification only when sufficient material is available. Ideal TBC size remains to be defined, but experts suggest that 5 × 5 mm (25 mm2) should be appropriate in most cases (T. Colby, MD, personal communication, November 2016), a size that is consistently attained with the 1.9- and 2.4-mm probes but exceeds the sheath cryobiopsy size reported in this study. Clearly, more research will be needed to determine their clinical utility in the diagnosis of diffuse parenchymal lung disease. As discussed in the accompanying editorial to our manuscript, there is a significant potential benefit for the sheath cryoprobe approach toward improving diagnostic yield in lung cancer as well as other disease entities lacking sufficient bronchoscopic diagnostic yields, such as early rejection in lung transplantation.